Does Rallies show Form 4 insider transactions for ANAB?

Yes. Rallies tracks ANAB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ANAB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ANAB. It does not provide personalized investment advice.

ANAB (AnaptysBio, Inc. Common Stock) Stock Analysis - Insider Trades

AnaptysBio, Inc. Common Stock (ANAB) is a publicly traded Healthcare sector company. As of May 21, 2026, ANAB trades at $60.06 with a market cap of $1.71B and a P/E ratio of -64.24. ANAB moved +0.50% today. Year to date, ANAB is +39.07%; over the trailing twelve months it is +184.74%. Its 52-week range spans $12.21 to $73.30. Analyst consensus is strong buy with an average price target of $81.27. Rallies surfaces ANAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ANAB stock inside the company?

Recent ANAB insider activity includes Schmid John P. sold 12.60K, Schmid John P. sold 7.53K, Schmid John P. sold 522, Faga Daniel sold 510, and Faga Daniel sold 2.57K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ANAB Key Metrics

Key financial metrics for ANAB
Metric	Value
Price	$60.06
Market Cap	$1.71B
P/E Ratio	-64.24
EPS	$-0.94
Dividend Yield	0.00%
52-Week High	$73.30
52-Week Low	$12.21
Volume	12
Avg Volume	0
Revenue (TTM)	$232.39M
Net Income	$-26.79M
Gross Margin	0.00%

Recent ANAB Insider Trades

Schmid John P. sold 12.60K (~$701.71K) on Mar 30, 2026.
Schmid John P. sold 7.53K (~$426.78K) on Mar 30, 2026.
Schmid John P. sold 522 (~$29.96K) on Mar 30, 2026.
Faga Daniel sold 510 (~$28.87K) on Mar 27, 2026.
Faga Daniel sold 2.57K (~$148.82K) on Mar 27, 2026.

Latest ANAB News

AnaptysBio Spin-Off Spurs 14.8% Rally as Jemperli Royalty Model Debuts — May 1, 2026
AnaptysBio Spin-Off Yields $140M Cash and >95% EBIT Margin — Apr 20, 2026
Anaptys approves $100M buyback and First Tracks $180M spin-off — Mar 27, 2026
AnaptysBio to Separate RoyaltyCo Holding Jemperli Rights and Biopharma Unit with $310M Cash — Mar 4, 2026
AnaptysBio Q4 EPS Rises to $1.58, Revenues Jump 151% to $108M — Mar 3, 2026

ANAB Analyst Consensus

11 analysts cover ANAB: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $81.27.

Common questions about ANAB

Who is trading ANAB stock inside the company?: Recent ANAB insider activity includes Schmid John P. sold 12.60K, Schmid John P. sold 7.53K, Schmid John P. sold 522, Faga Daniel sold 510, and Faga Daniel sold 2.57K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ANAB?: Yes. Rallies tracks ANAB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ANAB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ANAB. It does not provide personalized investment advice.